Cardiovascular Safety and Development of Type 2 Diabetes Mellitus Medications: Current State of the Art and Opportunities to Advance the Science

Börje C. Darpö, MD, PhD

Chief Scientific Officer, Cardiac Safety

Representative Invited

FDA, United States

FDA’S SENTINEL INITIATIVE — A NATIONAL STRATEGY FOR MONITORING MEDICAL PRODUCT SAFETY

Judith Racoosin, MD, MPH

FDA, United States

Sentinel Initiative, Scientific Lead, Office of the Commissioner, FDA

CV POST-MARKETING RISK ASSESSMENT: ACADEMIC VIEWPOINT

Allison B. Goldfine, MD

Joslin Diabetes Center, United States

Head, Section of Clinical Research